Company of the week: Avalyn Pharma - Inhaled Therapeutics for Pulmonary Fibrosis
Avalyn Pharma represents a compelling yet high-risk opportunity in the rapidly evolving pulmonary fibrosis therapeutics market. The company's
Fund of the week: Concentra
Tang Capital's contrarian strategy targets the 300 "zombie" companies holding $30 billion in trapped capital
In
Digital Therapeutics Reimbursement Models in Europe and Asia
Overview of Digital Therapeutics and Reimbursement
Digital therapeutics (DTx) are evidence-based software interventions prescribed to treat or manage medical conditions.
Europe’s Grand HTA Experiment: Unifying Drug Assessments Across the EU
In January 2025, a long-awaited experiment in European healthcare quietly began. For the first time, all EU countries have started
Comparative Regulatory Approaches to AI in Drug Development (as of July 2025)
Advances in artificial intelligence (AI) are rapidly transforming drug development and clinical trials. Medicines regulatory agencies worldwide have responded by
The weekly term sheet (30)
During the week of July 21–25, 2025, the biopharmaceutical industry saw a flurry of deal-making worldwide. This included major
Basics of Pharma Deal Structuring: An Explainer for Biotech Professionals
Most biotech professionals are familiar with science and R&D, but deal press releases often include financial jargon that
Company of the week: Repare Therapeutics - A Contrarian Precision Oncology Company
Disclaimer: This analysis represents an opinion based on publicly available information and should not be considered investment advice. Please conduct
BioPharma Credit PLC: Lending on Life Sciences under the Microscope
BioPharma Credit PLC (BPCR) is a London-listed investment trust specializing in debt financing for the life sciences sector. Managed by
When the Deal Is the Discovery: Platform Biotechs as Perpetual Option Sellers
Introduction – Deals as the New Discovery
Platform biotech companies today often make headlines not for proven drugs, but for deals
